South Korea-based IGIS Asset Management has launched a real estate investment business focused on the life sciences sector. The new venture will be based in Singapore and involves IGIS Asia Investment Management (IGIS AIM), the Singapore-based arm of the business, and a Korean biopharmaceutical business called CHA Bio Group. The fund will invest in life science assets, including R&D and manufacturing facilities, medical centres, and hospitals. Plans include a Korea-based investment platform focused on life sciences properties IGIS and CHA claim will be the first platform in Korea. “The partnership will rely on IGIS’s past track record of real estate transactions and CHA’s expertise in the life sciences industry to gain first-mover advantage in providing life science real estate solutions in South Korea and overseas,” stated IGIS AIM. © 2023 funds global asia